Slum residents carry a heavy and uneven burden of hypertension and type 2 diabetes
Across 62 studies and 108,110 participants, hypertension and type 2 diabetes emerged as major but highly variable problems in urban slums. The pooled evidence did not point to a single uniform pattern; instead, prevalence swung sharply from setting to setting, with hypertension ranging from 4.2% to 52.5% and type 2 diabetes from 0.9% to 25.0%. Those spreads are not statistical noise alone. They reflect profound differences in access to screening, food environment, crowding, chronic stress, migration patterns, and the unequal reach of primary care in densely populated informal settlements.
The review focused on studies that defined hypertension using blood pressure of at least 140/90 mm Hg or reported type 2 diabetes prevalence. Searches ran through Ovid MEDLINE, Cochrane CENTRAL, and EMBASE from inception to December 2020. Two reviewers independently extracted data and assessed risk of bias using the Strengthening the Reporting of Observational Studies in Epidemiology guideline. Random-effects meta-analyses were used to pool prevalence estimates, and meta-regression examined whether estimates changed over calendar time.
The main message is blunt. Slum populations are not protected from cardiometabolic disease simply because they are poor.
Prevalence swung sharply across countries and even within countries
The breadth of the prevalence ranges signals more than regional diversity. In some communities, underdiagnosis likely suppressed measured prevalence; in others, repeated contact with urban risk factors may have pushed rates upward. Crowded housing, limited opportunities for physical activity, high salt intake, food insecurity that favors cheap processed calories, tobacco exposure, and delayed care can converge on the same arterial and metabolic pathway. Over time, that pathway produces endothelial dysfunction, vascular stiffness, and impaired glucose regulation—exactly the biological terrain that drives the rise of both diseases.
The meta-analysis did not present one neat global estimate that could be applied everywhere. Instead, it showed a pattern of heterogeneity large enough to make location-specific interpretation essential. Within-country variation was also apparent, which is clinically important because urban slums are often treated as interchangeable when they are not. Differences in local sanitation, tenure security, migration history, and health-system contact can create very different cardiometabolic profiles in settlements that look similar on a map.
Comparator data from India pointed in two directions at once
Only six studies included comparator data, and all were from the Indian subcontinent. In those comparisons, slum residents were 35% more likely to have hypertension than people living in rural comparator areas, yet 30% less likely to have hypertension than people in non-slum urban comparator areas. The direction of both findings matters.
Rural areas may still carry lower exposure to some urban dietary and behavioral risks, while non-slum city neighborhoods may concentrate other hazards, including more sedentary routines, higher obesity prevalence, and different patterns of care-seeking. Slum residence therefore does not map cleanly onto either rural deprivation or formal urban advantage. It occupies a distinct position in the cardiometabolic gradient, shaped by urban exposure without the full protections of urban infrastructure.
This comparison also carries a practical warning. Screening strategies built for city hospitals may miss the people most likely to arrive late with uncontrolled disease, while rural programs may underestimate the urban poor who live in dense settlements but remain outside formal care networks.
The diabetes burden tracks the same structural pressures
Prevalence of type 2 diabetes ranged from 0.9% to 25.0%, a spread wide enough to suggest major differences in case ascertainment as well as true disease burden. Where access to laboratory testing is limited, diabetes prevalence will often be undercounted. Where opportunistic testing is more available, detection rises. Even so, the upper end of the range indicates that some slum populations already face a substantial glycemic burden, likely amplified by chronic psychosocial stress, dietary transition, and low continuity of care.
The biological link between urban poverty and metabolic disease is straightforward. Persistent stress activation alters neuroendocrine signaling, worsens insulin resistance, and can raise blood pressure through sympathetic and renal mechanisms. At the same time, a reliance on low-cost calorie-dense foods and reduced opportunities for safe exercise can compound both adiposity and glucose dysregulation. In slum settings, these drivers often accumulate before diagnosis, leaving patients to present with complications rather than risk-factor control.
The evidence base is informative but still incomplete
The review’s limitations are important because they constrain how far the findings can be generalized. Only a small number of studies compared slum residents directly with rural and non-slum urban populations, and those comparisons came from one broad geographic region. That leaves large parts of the world without direct head-to-head evidence. The prevalence estimates were also drawn from studies with differing designs, sampling frames, and local diagnostic practices, all of which can widen apparent variation.
Even so, the review provides a useful epidemiologic map. It shows that slum populations should not be treated as a single homogeneous group and that cardiometabolic surveillance cannot rely on national averages alone. Health systems that overlook informal settlements risk missing a large reservoir of undiagnosed disease, especially where routine blood pressure measurement and glucose testing are scarce.
Screening and primary care have to reach informal settlements
For clinicians and public health planners, the implication is operational rather than abstract. Blood pressure checks, diabetes case-finding, and continuity of medication need to be built into services that actually reach slum communities. Without that, the first contact will often be an emergency department or an advanced complication clinic, where prevention has already failed. The review also argues for more local data, because the burden varied widely between countries and within countries, making blanket assumptions unreliable.
Future work needs stronger comparator studies across more regions, with consistent diagnostic methods and clearer community sampling. Until those data exist, the safest interpretation is straightforward: hypertension and type 2 diabetes are already established threats in urban slums, but their measured burden depends heavily on where and how they are sought.